These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 18601833)

  • 1. [Use of antibiotics for the treatment of multiresistant gram positive cocci infections in critical patients].
    Rodríguez Colomo O; Alvarez Lerma F; Alvarez Sánchez B; Oltra Chordá R; Barcenilla Gaite F; Cereijo Martín-Grande E; Cuñat de la Hoz J; Martínez Pellús A;
    Med Intensiva; 2008; 32(6):263-71. PubMed ID: 18601833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis of treatments used in infections caused by gram-positive multiresistant cocci in critically ill patients admitted to the ICU].
    Álvarez-Lerma F; Palomar Martínez M; Olaechea Astigarraga P; Insausti Ordeñana J; López Pueyo MJ; Gracia Arnillas MP; Gimeno Costa R; Seijas Betolaza I
    Rev Esp Quimioter; 2012 Mar; 25(1):65-73. PubMed ID: 22488544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of linezolid in critically ill patients admitted to intensive care units.
    Rodríguez O; Alvarez F; Oltra R; Cereijo E; Latorre MM; Martínez H;
    Rev Esp Quimioter; 2009 Jun; 22(2):68-75. PubMed ID: 19554485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibiotics for gram-positive bacterial infections. Vancomycin, teicoplanin, quinupristin/dalfopristin, and linezolid.
    Lundstrom TS; Sobel JD
    Infect Dis Clin North Am; 2000 Jun; 14(2):463-74. PubMed ID: 10829266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Linezolid more efficacious than vancomycin to eradicate infecting organism in critically ill patients with Gram-positive infections.
    Sirvent JM; Piñeiro L; de la Torre M; Motjé M; de Batlle J; Bonet A
    Rev Esp Quimioter; 2010 Mar; 23(1):27-35. PubMed ID: 20232021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens.
    Jantausch BA; Deville J; Adler S; Morfin MR; Lopez P; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
    Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S164-71. PubMed ID: 14520142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study.
    Cepeda JA; Whitehouse T; Cooper B; Hails J; Jones K; Kwaku F; Taylor L; Hayman S; Shaw S; Kibbler C; Shulman R; Singer M; Wilson AP
    J Antimicrob Chemother; 2004 Feb; 53(2):345-55. PubMed ID: 14711840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro susceptibility of Gram-positive pathogens to linezolid and teicoplanin and effect on outcome in critically ill patients.
    Wilson AP; Cepeda JA; Hayman S; Whitehouse T; Singer M; Bellingan G
    J Antimicrob Chemother; 2006 Aug; 58(2):470-3. PubMed ID: 16735420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapeutic perspectives of linezolid in the management of infections due to multiresistant Gram-positive pathogens].
    Manfredi R
    Recenti Prog Med; 2007 Mar; 98(3):143-54. PubMed ID: 17484159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New treatment option for gram-positive infections in critically ill patients - overview over linezolid].
    Krueger WA; Unertl KE
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2002 Apr; 37(4):199-204. PubMed ID: 11967745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early microbiological response to linezolid vs vancomycin in ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus.
    Wunderink RG; Mendelson MH; Somero MS; Fabian TC; May AK; Bhattacharyya H; Leeper KV; Solomkin JS
    Chest; 2008 Dec; 134(6):1200-1207. PubMed ID: 18719064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparison of teicoplanin and linezolid therapies in patients with methicillin-resistant Staphylococcus aureus pneumonia acquired from respiratory intensive care unit].
    Taşbakan MS; Korkmaz Ekren P; Pullukçu H; Başarık B; Susur A; Aydemir S; Başoğlu OK; Bacakoğlu F
    Mikrobiyol Bul; 2010 Jul; 44(3):357-66. PubMed ID: 21063985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quinupristin-dalfopristin versus linezolid for the treatment of vancomycin-resistant Enterococcus faecium bacteraemia: efficacy and development of resistance.
    Chong YP; Lee SO; Song EH; Lee EJ; Jang EY; Kim SH; Choi SH; Kim MN; Jeong JY; Woo JH; Kim YS
    Scand J Infect Dis; 2010 Jul; 42(6-7):491-9. PubMed ID: 20524781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial activity of linezolid against Gram-positive cocci isolated in Brazil.
    Sader HS; Gales AC; Jones RN
    Braz J Infect Dis; 2001 Aug; 5(4):171-6. PubMed ID: 11712961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children.
    Kaplan SL; Deville JG; Yogev R; Morfin MR; Wu E; Adler S; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB;
    Pediatr Infect Dis J; 2003 Aug; 22(8):677-86. PubMed ID: 12913766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and tolerability of linezolid in children.
    Saiman L; Goldfarb J; Kaplan SA; Wible K; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
    Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S193-200. PubMed ID: 14520146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vancomycin-resistant enterococcal bacteremia pharmacotherapy.
    Patel R; Gallagher JC
    Ann Pharmacother; 2015 Jan; 49(1):69-85. PubMed ID: 25352037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two new treatment options for infections due to drug-resistant gram-positive cocci.
    Rehm SJ
    Cleve Clin J Med; 2002 May; 69(5):397-401, 405-13. PubMed ID: 12022383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study.
    Wilcox MH; Tack KJ; Bouza E; Herr DL; Ruf BR; Ijzerman MM; Croos-Dabrera RV; Kunkel MJ; Knirsch C
    Clin Infect Dis; 2009 Jan; 48(2):203-12. PubMed ID: 19072714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment options for vancomycin-resistant enterococcal infections.
    Linden PK
    Drugs; 2002; 62(3):425-41. PubMed ID: 11827558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.